Results 181 to 190 of about 2,751,693 (208)
Some of the next articles are maybe not open access.
Molecular mechanisms of resistance of leukemia to imatinib mesylate
Leukemia Research, 2004Despite high rates of hematologic and cytogenetic responses to imatinib therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of Ph-positive leukemia. The high frequency of BCR-ABL mutations and amplifications represents the high degree of heterogeneity in patients with advanced phase of CML, in whom ...
Tetsuzo, Tauchi, Kazuma, Ohyashiki
openaire +2 more sources
Blood, 2005
Abstract Chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) are caused by the Bcr-Abl tyrosine kinase oncogene. The Abl inhibitor imatinib is an effective, frontline therapy for early, chronic phase CML. However, accelerated or blast crisis phase CML and Ph+ ALL patients often
James D. Griffin, Ellen L. Weisberg
openaire +1 more source
Abstract Chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) are caused by the Bcr-Abl tyrosine kinase oncogene. The Abl inhibitor imatinib is an effective, frontline therapy for early, chronic phase CML. However, accelerated or blast crisis phase CML and Ph+ ALL patients often
James D. Griffin, Ellen L. Weisberg
openaire +1 more source
Gastroenterology, 2005
Resistance is a major challenge in the treatment of patients with gastrointestinal stromal tumors (GISTs). We investigated the mechanisms of resistance in patients with progressive GISTs with primary KIT mutations and the efficacy of the kinase inhibitor PKC412 for the inhibition of imatinib-resistant mutants.We performed a cytogenetic analysis and ...
Dębiec-Rychter, M. +12 more
openaire +2 more sources
Resistance is a major challenge in the treatment of patients with gastrointestinal stromal tumors (GISTs). We investigated the mechanisms of resistance in patients with progressive GISTs with primary KIT mutations and the efficacy of the kinase inhibitor PKC412 for the inhibition of imatinib-resistant mutants.We performed a cytogenetic analysis and ...
Dębiec-Rychter, M. +12 more
openaire +2 more sources
Roots of imatinib resistance: A question of self-renewal?
Drug Resistance Updates, 2007The BCR-ABL-fusion gene is critical for the development of chronic myeloid leukemia (CML) and BCR-ABL positive acute lymphatic leukemia (Ph+ ALL). Blocking BCR-ABL by the ABL tyrosine kinase inhibitor imatinib mesylate (IM, Gleevec) is clinically highly efficient.
openaire +2 more sources
Novel approaches to imatinib-and sunitinib-resistant GIST
Current Oncology Reports, 2008Gastrointestinal stromal tumors (GISTs) generally arise from primary activating mutations in the KIT or PDGFRA genes that result in constitutive activation of receptor tyrosine kinase activity. Imatinib provides targeted therapy for GIST by inhibiting the KIT and PDGFR-alpha tyrosine kinases.
openaire +2 more sources
New Directions in the Treatment of Imatinib Failure and/or Resistance
Seminars in Hematology, 2009For the minority of chronic myeloid leukemia (CML) patients who demonstrate primary or secondary resistance or intolerance to first-line imatinib therapy, previously available treatment options were limited to cytotoxic chemotherapy, interferon alfa, or allogeneic hematopoietic stem cell transplantation.
openaire +2 more sources
YM155 Restores the Effect of Imatinib in Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
Current Cancer Drug TargetsIntroduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome. Imatinib is considered the standard therapy for CML due to its targeted action against the BCR::ABL1 tyrosine kinase.
Belal A. Al-Husein +3 more
openaire +2 more sources
Antibiotic Resistance in the Patient With Cancer: Escalating Challenges and Paths Forward
Ca-A Cancer Journal for Clinicians, 2021Amila K Nanayakkara +2 more
exaly

